Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment

Abstract Cancer-related cognitive impairment (CRCI) has not been objectively assessed in chronic lymphocytic leukemia (CLL). It is currently unclear how much of CRCI is attributable to disease, treatment, or both. We used CLL as a novel model to study the differential roles of disease and treatment in CRCI. One hundred and fifty CLL patients (100 treatment-naïve and 50 chemotherapy-treated) including 84 patients with higher-risk of CLL progression completed objective neuropsychological tests. Sociodemographic-adjusted linear regression models examined cognitive outcomes in relation to risk and treatment. Higher-risk patients recalled two fewer words on a memory task (β = −1.8, 95%CI –3.3,−0.3) and took 15 s longer on an executive function task (β = 15.4, 95%CI 3.1, 27.6) than lower-risk patients, independent of treatment. Treated patients reported greater cognitive difficulties than treatment-naive patients (β = −6.1, 95%CI –10.1, −2.2) but did not perform worse on objective measures. Higher-risk patients experienced impairments in executive function and memory suggesting that disease biology contributes to CRCI independent of treatment.

[1]  J. Grellard,et al.  Impact of anxio-depressive symptoms and cognitive function on oral anticancer therapies adherence , 2019, Supportive Care in Cancer.

[2]  H. Dhillon,et al.  Important differences and meaningful changes for the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) , 2018, Journal of Patient-Reported Outcomes.

[3]  L. Minasian,et al.  Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Byrd,et al.  iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.

[5]  G. Abel,et al.  Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers , 2018, JAMA oncology.

[6]  M. Janelsins,et al.  Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies , 2018, Leukemia & lymphoma.

[7]  Ronald C. Petersen,et al.  Practice guideline update summary: Mild cognitive impairment , 2018, Neurology.

[8]  Bryan D. Thompson,et al.  Associations between inflammatory markers and cognitive function in breast cancer patients receiving chemotherapy , 2018, Journal of Neuroimmunology.

[9]  C. Heckler,et al.  Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Theresa A. Koleck,et al.  Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer , 2017, Cancer medicine.

[11]  C. Pui,et al.  Cognitive, behaviour, and academic functioning in adolescent and young adult survivors of childhood acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study. , 2016, The lancet. Psychiatry.

[12]  M. D. de Ruiter,et al.  Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. , 2015, Journal of pain and symptom management.

[13]  S. O'brien,et al.  Initial treatment of CLL: integrating biology and functional status. , 2015, Blood.

[14]  Eileen F. Tallman,et al.  Perceived cognitive function in breast cancer survivors: evaluating relationships with objective cognitive performance and other symptoms using the functional assessment of cancer therapy-cognitive function instrument. , 2015, Journal of pain and symptom management.

[15]  Kyle R. Noll,et al.  Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer‐related cognitive impairment in adults , 2015, CA: a cancer journal for clinicians.

[16]  A. Mierau,et al.  Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine , 2015, Leukemia & lymphoma.

[17]  N. Fox,et al.  Cognition assessment using the NIH Toolbox , 2013, Neurology.

[18]  D. Catovsky,et al.  Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial , 2012, Leukemia & lymphoma.

[19]  N. Kay,et al.  Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach , 2011, Leukemia & lymphoma.

[20]  T. Ahles,et al.  International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. , 2011, The Lancet. Oncology.

[21]  J. Morris,et al.  Four sensitive screening tools to detect cognitive dysfunction in geriatric emergency department patients: brief Alzheimer's Screen, Short Blessed Test, Ottawa 3DY, and the caregiver-completed AD8. , 2011, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[22]  M. Perry,et al.  Cognitive and Psychological Factors Associated with Early Posttreatment Functional Outcomes in Breast Cancer Survivors , 2009, Journal of psychosocial oncology.

[23]  S. Subramanian,et al.  Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response , 2009, Journal of cancer survivorship : research and practice.

[24]  Andrew J. Saykin,et al.  Candidate mechanisms for chemotherapy-induced cognitive changes , 2007, Nature Reviews Cancer.

[25]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[26]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[27]  A. Mackinnon,et al.  Measurement properties of the Center for Epidemiological Studies Depression Scale: an Australian community study of aged persons. , 1995, The journals of gerontology. Series B, Psychological sciences and social sciences.

[28]  E. Smets,et al.  The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. , 1995, Journal of psychosomatic research.

[29]  P. Jacobsen,et al.  Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients. , 2007, Journal of pain and symptom management.

[30]  C. Spielberger,et al.  Measuring anxiety and anger with the State-Trait Anxiety Inventory (STAI) and the State-Trait Anger Expression Inventory (STAXI). , 1999 .

[31]  H. Levin,et al.  Benton Controlled Oral Word Association Test: reliability and updated norms. , 1996, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[32]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .